Gosset Ownership
Private
Employees
~163
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Stragen General Information
Stragen specializes in the development and commercialization of hard-to-make generic medicines and niche hospital pharmaceuticals with a focus on life-threatening conditions requiring intensive care. The company operates globally across more than sixty countries with a strong presence in Europe. Its portfolio covers oncology, cardiology, neurology, anti-infectives/antifungals as well as women’s health. In addition to generics and consumer health products—including natural formulations—Stragen invests in the development of patented new drugs addressing orphan diseases or unmet medical needs.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Geneva / Plan-les-Ouates,
Switzerland
Switzerland
Drug Pipeline
chartreusin
Phase 2Key Partnerships
Works with an extensive network of partners for global distribution but no specific major pharma partnerships named.
Stragen Funding
No funding data available
To view Stragen's complete valuation and funding history, request access »